<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453555</url>
  </required_header>
  <id_info>
    <org_study_id>1275.19</org_study_id>
    <nct_id>NCT02453555</nct_id>
  </id_info>
  <brief_title>Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial will compare the use of fiixed dose conbination of empagliflozin and linagliptin
      to linagliptine alone in patient with type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2015</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of glycosylated haemoglobin A1c (glycosylated haemoglobin A1c after 24 weeks of doubleblind treatment from baseline)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from Week 28 at Week 52 (empagliflozin high dose/linagliptin FDC only)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline at Week 52 (empagliflozin1/linagliptin FDC versus linagliptin plus placebo)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline at Week 52 (empagliflozin high dose/linagliptin FDC versus placebo for empagliflozin high dose/linagliptin FDC)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline at Week 52 (empagliflozin high ose/linagliptin FDC versus linagliptin plus placebo)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive 5 mg linagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin + linagliptin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin + linagliptin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin placebo + linagliptin placebo</intervention_name>
    <description>Matching placebo empagliflozin + linagliptin</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin + linagliptin low dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>Empagliflozin + linagliptin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin lacebo</intervention_name>
    <description>Matching placebo linagliptin</description>
    <arm_group_label>Empagliflozin + linagliptin low dose</arm_group_label>
    <arm_group_label>Empagliflozin + linagliptin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin + linagliptin high dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>Empagliflozin + linagliptin high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of T2DM prior to informed consent

          2. Male and female patients on diet and exercise regimen for at least 12 weeks prior to
             informed consent who are:

               -  1 drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent, or

               -  2 pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half
                  of the maximum approved dose) on stable dosage for at least 12 weeks prior to
                  informed consent (for thiazolidinedione, therapy has to be unchanged for at least
                  18 weeks prior to the informed consent, for linagliptin 5 mg at least 16 weeks
                  prior to Visit 1). Individual antidiabetic drug (except linagliptin) will have to
                  be discontinued at Visit 1.

          3. HbA1c at Visit 1

               -  1 HbA1c =8.0% and =10.5% for patients who are drug-naïve, or

               -  2 HbA1c =7.5% and =10.5% for patients with one oral antidiabetic drug (except
                  linagliptin), or

               -  3 HbA1c =7.5% and =10.0% for patients with linagliptin 5 mg

          4. HbA1c =7.5% and =10.0% at Visit 4 for randomisation into the double-blind treatment
             period. Patient who are pre-treated with linagliptin 5 mg for 16 weeks or more prior
             to Visit 1 and meet the criteria of HbA1c can directly move on to the run-in (Visit
             4).

          5. Age =20 years at informed consent

          6. BMI =40.0 kg/m2 at Visit 1 (screening)

          7. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          1. Uncontrolled hyperglycemia with a glucose level &gt;270 mg/dL (&gt;15.0 mmol/L) after an
             overnight fast during the open-label stabilisation period (from Visit 2 to Visit 4)
             and run-in period (from Visit 4 to Visit 5) , confirmed by a second measurement (not
             on the same day and done either at the central or at local laboratory).

          2. Acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI, and
             unstable angina pectoris), stroke or transient ischemic attack within 12 weeks prior
             to informed consent

          3. Indication of liver disease, defined by serum levels of either alanine
             aminotransferase (ALT [SGPT]), aspartate aminotransferase (AST [SGOT]), or alkaline
             phosphatase (ALP) above 3 x upper limit of normal (ULN) as determined during
             screening, open-label stabilisation period and/or run-in period

          4. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;45
             mL/min/1.73 m2 (MDRD formula) as determined during screening, open-label stabilisation
             period and/or run-in period

          5. Known hereditary galactose intolerance

          6. Known contraindications to linagliptin and empagliflozin according to the Japanese
             label

          7. Any previous (within 2 years prior to informed consent) or planned bariatric surgery
             (or any other weight loss surgery) or other gastrointestinal surgery that induce
             chronic malabsorption

          8. Medical history of cancer (except for resected non-invasive basal cell or squamous
             carcinoma) and/or treatment for cancer within the last 5 years

          9. Known blood dyscrasias or any disorders causing haemolysis or unstable red blood cell
             (RBC) count (e.g. malaria, babesiosis, haemolytic anaemia).

         10. Treatment with insulin, GLP-1 agonists, within 12 weeks prior to informed consent

         11. Treatment with anti-obesity drugs within 12 weeks prior to informed consent or any
             other treatment at the time of screening (i.e., surgery, aggressive diet regimen,
             etc.) leading to unstable body weight

         12. Current treatment with systemic steroids (other than inhaled or topical steroids) at
             informed consent or change in dosage of thyroid hormones within 6 weeks prior to
             informed consent or any other uncontrolled endocrine disorder except T2DM

         13. Pre-menopausal women (last menstruation =1 year prior to informed consent) who:

               -  1 are nursing or pregnant or

               -  2 are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the trial
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include tubal ligation, intra
                  uterine devices/systems, oral contraceptives, complete sexual abstinence, double
                  barrier method and vasectomised partner

         14. Known or suspected allergy or hypersensitivity to trial products or related products
             (e.g., DPP-4 inhibitors or SGLT-2 inhibitors)

         15. Alcohol or drug abuse within the 12 weeks prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to trial procedures or trial drug intake, by the judgment of the
             investigator

         16. Intake of an investigational drug in another trial within 30 days prior to Visit 1 or
             participation in the follow-up period of another trial (participation in observational
             studies is permitted)

         17. Any other clinical condition that, in the opinion of the investigator, would
             jeopardize patient¿s safety while participating in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1275.19.81519 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81536 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81530 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81529 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Itoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81531 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukushima, Koriyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81528 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81532 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Koga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81533 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Naka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81516 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81537 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81538 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81520 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81521 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81539 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81517 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81518 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81525 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Higashi-Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81523 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81526 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81527 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81540 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81522 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81524 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81535 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Hanno</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Kawagoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81534 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Tokorozawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81512 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81515 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81511 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81513 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Meguro-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81514 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.19.81510 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 23, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 19, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

